Company Broadens Product Portfolio with Assay Controls, Ignites Drive for Growth in Disease Diagnostics
MALVERN, Pa.--(BUSINESS WIRE)--Fujirebio Diagnostics, a world leader in cancer diagnostics and biomarker assays, announced today it has acquired American Biological Technologies, the Seguin, Texas-based manufacturer of in vitro diagnostic assay controls and calibrators. Marking Fujirebio Diagnostics’ entry into the controls and calibrators manufacturing business, the merger will enable the company to further strengthen its position in the evolving in vitro diagnostics industry.
“For more than 20 years, Fujirebio Diagnostics has been on the forefront of oncology diagnostics, bringing to market vital biomarker assays that enable clinicians to better manage cancer,” said Paul Touhey, president and CEO of Fujirebio Diagnostics. “The acquisition is a natural next step on our path in entering diagnostic assay control and calibrator manufacturing, and mirrors Fujirebio Diagnostics’ strategy to provide its diagnostic industry customers with the tools and services that will revolutionize how disease is diagnosed and managed.”
American Biological Technologies has served as one of Fujirebio Diagnostics’ main suppliers for several years, providing controls and calibrators to a shared customer base. Controls and calibrators are used to confirm that diagnostic assay kits and the analyzers that the kits run on are performing within specification and as such complement Fujirebio Diagnostics’ broad portfolio of diagnostic assays. With the union of the two companies, both new and existing industry customers will benefit from enhanced, streamlined delivery of material used in products sold to laboratory customers.
“By combining American Biological Technologies’ control products and manufacturing capabilities with Fujirebio Diagnostics’ extensive knowledge of in-vitro diagnostics, marketing resources and established customer relationships and partnerships, we’ll truly be able to realize the potential for the American Biological Technologies product offering to take our business to the next level of disease diagnostics,” adds Monte Wiltse, vice president of marketing and sales.
The products developed by American Biological Technologies are designed to work with a wide variety of diagnostic equipment and in virtually any diagnostic laboratory. While Fujirebio Diagnostics specializes in oncology diagnostics, Wiltse notes that the versatility of these products will enable Fujirebio Diagnostics to tap into the management of diseases beyond cancer such as diabetes.
About Fujirebio Diagnostics
Fujirebio Diagnostics is the premier cancer diagnostics company and the industry leader in cancer biomarker assays. Fujirebio Diagnostics specializes in the clinical development, manufacturing and commercialization of in-vitro diagnostic products for the management of human disease states, with an emphasis in oncology. Fujirebio Diagnostics is a wholly owned subsidiary of Fujirebio Inc. Fujirebio Inc. is a leading healthcare company in Japan with a focus on diagnostics, and is a group company of Miraca Holdings. Fujirebio Diagnostics has a worldwide distribution network which enables physicians and patients to access its diagnostic products. For more information about Fujirebio Diagnostics, please call 610-240-3800 or visit www.fdi.com.
Contact:
Stern + Associates Stephanie Euler, (908) 276-4344 ext. 213 stephanie@sternassociates.com
Source: Fujirebio Diagnostics
